Axxam S.p.A. is a CRO delivering integrated early drug discovery, from target identification to lead generation. Through its DiscoveryMAXX platform, it supports pharma, biotech, start-ups, and academia with biology-driven solutions across all therapeutic areas and target classes.
Products, services, technology
- AI-enhanced target identification with wet-lab validation
- Assay development
- Compound management
- Fully-automated HTS
- Virtual screening
- Hit profiling
- Access to physical and virtual libraries
- Early in vitro efficacy, biodistribution, and toxicity using NAMs
- http://www.axxam.com
- +39 02 21 05 61
- Send an email
- Paola Picardi
Some insights
Axxam's ultimate goal is to lead the way in life sciences and create solutions that redefine what is possible, and inspiring a healthier, more sustainable world.
Axxam's clients expressed many times deep gratitude and compliments for the expert quality and dedication delivered by the Axxam scientific team.
Our team consists of early-stage drug discovery experts driven to tackle complex challenges. We prioritize quality, data security, precision, and collaboration. We integrate AI-based drug discovery, bioinformatics, and advanced computational biology skills.
The Swiss biotech ecosystem can support Axxam by fostering collaborations with innovative biotech companies, facilitating access to cutting-edge technologies, and creating networking opportunities with key stakeholders focused on drug discovery and development.
At Axxam, we connect with key players in pharma, biotech, and life sciences focused on discovering new drugs and improving global health. We collaborate with innovators seeking advanced solutions in assay development, high-throughput screening, and integrated drug discovery.
